Company History
Biomedix is a fast-growing company in the San Francisco bay area that is devoted to the making of medical biosensor. It is one of the companies that offer Dual Monitoring System to measure two different analysts in the blood. For example, both glucose and cholesterol can be measured within our dual monitoring system. And the testing for many other more new analysts in the blood are under development. Our system is small enough to carry in a package but yet versatile enough perform two vastly different tasks, even three or more.

Through many year's improvement our management and development, our product's features enable us to meet the greatest challenge, and to keep our customer in their best benefits. At the same time, we are able to compete within the medical industries.

Customer service is always our main mission. Company objective is to assist our customer in loving their life, caring their health. With the fair product price and the best after service to benefits our patents is always our first priority.

The Establishment of R&D Department
Biomedix Research and Development Department was first established by distinguished professors: Professor Paul Shieh from University of California, Berkeley, whose research has been focused on biosensor with more than fifty publications and patents; Dr. Herman Lau from the University of Chicago, whose research mainly focused on Enzymology and Protein Chemistry; Professor Ding Li Guo from Cheng-Dou University of Science and Technology Sichuan, China with over hundred publications in biosensor and author of "Sensing Membrane Electrode, SME".

Core Technology
The Biomedix core technology is an enabling technology which provides a platform for multiple products in the Biomedical, Environmental and Industrial testing areas. This technology provides many opportunities for product licensing in many markets worldwide. Such technology offers:

• Very diverse analytical applications.
• High sensitivity and selectivity electrochemical detection methods.
• Revolutionary patented sensor configuration enables the enhancement of reaction response.
• Cost effective and high yield manufacturing capacities.
• Simplicity to end users allowing unskilled operators and to obtain very accurate and precise results.

The R&D goal is to create innovative new product design based on the company's patents and other proprietary technology.

Businesses
January, 2009
Establish world-wide distributionship for Biomedix's product: Q.Steps G/C dual monitoring system.

November, 2005
Granted import sale permit from Chinese FDA for Glucose System.

August 9th, 2005
Received another 501K for Dual Monitoring System in measuring glucose and cholesterol from the blood.

May 24th 2004
Received 501K for Glucose Monitoring System from FDA to manufacture and sale in the USA.

June 2004
Established the distribution channel in the USA, Europe, Central and South America, Far East Asia and Middle East.

2002 - 2004
Biomedix, Inc., invested and established its own GMP manufacture facility at the headquarter and Taipei, Taiwan plant to mass production products.

1998
Obtained import sale permit from Chinese government allowing the sales of Biomedix product in China

1992 - 1999
Biomedix, Inc., have developed nine (9) US patents of our own platform technologist face-to-face biosensor to detect glucose, cholesterol in the blood and urine samples.